Previous Article | Next Article 
Journal of Virology, September 2000, p. 8390-8401, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse
Transcriptase Inhibitors Demonstrate Altered Rates of RNase H
Cleavage That Correlate with HIV-1 Replication Fitness in
Cell Culture
Richard H.
Archer,1
Carrie
Dykes,1
Peter
Gerondelis,1,2
Amanda
Lloyd,1
Philip
Fay,1,3,4
Richard
C.
Reichman,1,2
Robert A.
Bambara,2,3,4 and
Lisa M.
Demeter1,2,4,*
Departments of
Medicine,1 Microbiology and
Immunology,2 Biochemistry and
Biophysics,3 and the Cancer
Center,4 University of Rochester School of
Medicine and Dentistry, Rochester, New York 14642
Received 4 January 2000/Accepted 7 June 2000
Three mutants of human immunodeficiency virus type 1 (HIV-1)
reverse transcriptase (V106A, V179D, and Y181C), which occur in
clinical isolates and confer resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), were analyzed for RNA- and DNA-dependent DNA polymerization and RNase H cleavage. All mutants demonstrated processivities of polymerization that were
indistinguishable from wild-type enzyme under conditions in which
deoxynucleoside triphosphates were not limiting. The V106A reverse
transcriptase demonstrated a three- to fourfold slowing of both DNA
3'-end-directed and RNA 5'-end-directed RNase H cleavage relative to
both wild-type and V179D enzymes, similar to what was observed for
P236L in a previously published study (P. Gerondelis et al., J. Virol. 73:5803-5813, 1999). In contrast, the Y181C reverse
transcriptase demonstrated a selective acceleration of the secondary
RNase H cleavage step during both modes of RNase H cleavage. The
relative replication fitness of these mutants in H9 cells was assessed
in parallel infections as well as in growth competition experiments. Of
the NNRTI-resistant mutants, V179D was more fit than Y181C, and both of
these mutants were more fit than V106A, which demonstrated the greatest
reduction in RNase H cleavage. These findings, in combination with
results from previous work, suggest that abnormalities in RNase H
cleavage are a common characteristic of HIV-1 mutants resistant to
NNRTIs and that combined reductions in the rates of DNA 3'-end- and RNA
5'-end-directed cleavages are associated with significant reductions in
the replication fitness of HIV-1.
*
Corresponding author. Mailing address: University of
Rochester Infectious Diseases Unit, 601 Elmwood Ave., Box 689, Rochester, NY 14642. Phone: (716) 275-4764. Fax: (716) 442-9328. E-mail: Lisa_Demeter{at}urmc.rochester.edu.
Journal of Virology, September 2000, p. 8390-8401, Vol. 74, No. 18
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Dykes, C., Demeter, L. M.
(2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev.
20: 550-578
[Abstract]
[Full Text]
-
Purohit, V., Roques, B. P., Kim, B., Bambara, R. A.
(2007). Mechanisms That Prevent Template Inactivation by HIV-1 Reverse Transcriptase RNase H Cleavages. J. Biol. Chem.
282: 12598-12609
[Abstract]
[Full Text]
-
Held, D. M., Kissel, J. D., Saran, D., Michalowski, D., Burke, D. H.
(2006). Differential Susceptibility of HIV-1 Reverse Transcriptase to Inhibition by RNA Aptamers in Enzymatic Reactions Monitoring Specific Steps during Genome Replication. J. Biol. Chem.
281: 25712-25722
[Abstract]
[Full Text]
-
Dykes, C., Wang, J., Jin, X., Planelles, V., An, D. S., Tallo, A., Huang, Y., Wu, H., Demeter, L. M.
(2006). Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.. J. Clin. Microbiol.
44: 1930-1943
[Abstract]
[Full Text]
-
Purohit, V., Balakrishnan, M., Kim, B., Bambara, R. A.
(2005). Evidence That HIV-1 Reverse Transcriptase Employs the DNA 3' End-directed Primary/Secondary RNase H Cleavage Mechanism during Synthesis and Strand Transfer. J. Biol. Chem.
280: 40534-40543
[Abstract]
[Full Text]
-
van der Hoek, L., Back, N., Jebbink, M. F., de Ronde, A., Bakker, M., Jurriaans, S., Reiss, P., Parkin, N., Berkhout, B.
(2005). Increased Multinucleoside Drug Resistance and Decreased Replicative Capacity of a Human Immunodeficiency Virus Type 1 Variant with an 8-Amino-Acid Insert in the Reverse Transcriptase. J. Virol.
79: 3536-3543
[Abstract]
[Full Text]
-
Meyer, P. R., Smith, A. J., Matsuura, S. E., Scott, W. A.
(2004). Effects of Primer-Template Sequence on ATP-dependent Removal of Chain-terminating Nucleotide Analogues by HIV-1 Reverse Transcriptase. J. Biol. Chem.
279: 45389-45398
[Abstract]
[Full Text]
-
Locatelli, G. A., Campiani, G., Cancio, R., Morelli, E., Ramunno, A., Gemma, S., Hubscher, U., Spadari, S., Maga, G.
(2004). Effects of Drug Resistance Mutations L100I and V106A on the Binding of Pyrrolobenzoxazepinone Nonnucleoside Inhibitors to the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Catalytic Complex. Antimicrob. Agents Chemother.
48: 1570-1580
[Abstract]
[Full Text]
-
Charpentier, C., Dwyer, D. E., Mammano, F., Lecossier, D., Clavel, F., Hance, A. J.
(2004). Role of Minority Populations of Human Immunodeficiency Virus Type 1 in the Evolution of Viral Resistance to Protease Inhibitors. J. Virol.
78: 4234-4247
[Abstract]
[Full Text]
-
Simon, V., Padte, N., Murray, D., Vanderhoeven, J., Wrin, T., Parkin, N., Di Mascio, M., Markowitz, M.
(2003). Infectivity and Replication Capacity of Drug-Resistant Human Immunodeficiency Virus Type 1 Variants Isolated during Primary Infection. J. Virol.
77: 7736-7745
[Abstract]
[Full Text]
-
Wirden, M., Simon, A., Schneider, L., Tubiana, R., Paris, L., Marcelin, A. G., Delaugerre, C., Legrand, M., Herson, S., Peytavin, G., Katlama, C., Calvez, V.
(2003). Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs. J. Clin. Microbiol.
41: 2713-2715
[Abstract]
[Full Text]
-
Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., Whitcomb, J. M.
(2002). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. J. Virol.
77: 1512-1523
[Abstract]
[Full Text]
-
Wisniewski, M., Chen, Y., Balakrishnan, M., Palaniappan, C., Roques, B. P., Fay, P. J., Bambara, R. A.
(2002). Substrate Requirements for Secondary Cleavage by HIV-1 Reverse Transcriptase RNase H. J. Biol. Chem.
277: 28400-28410
[Abstract]
[Full Text]
-
Shafer, R. W.
(2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev.
15: 247-277
[Abstract]
[Full Text]
-
KRYNETSKAIA, N. F., FENG, J. Y., KRYNETSKI, E. Y., GARCIA, J. V., PANETTA, J. C., ANDERSON, K. S., EVANS, W. E.
(2001). Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB J.
15: 1902-1908
[Abstract]
[Full Text]
-
Quer, J., Hershey, C. L., Domingo, E., Holland, J. J., Novella, I. S.
(2001). Contingent Neutrality in Competing Viral Populations. J. Virol.
75: 7315-7320
[Abstract]
[Full Text]
-
Imamichi, T., Murphy, M. A., Imamichi, H., Lane, H. C.
(2001). Amino Acid Deletion at Codon 67 and Thr-to-Gly Change at Codon 69 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Novel Drug Resistance Profiles. J. Virol.
75: 3988-3992
[Abstract]
[Full Text]